Hepatic Encephalopathy Market Analysis (2020-2027)

Hepatic encephalopathy (HE) is the complication of advanced liver disease. Hepatic encephalopathy is a major challenge to the healthcare system due to frequent hospital contacts and admissions. Hepatic encephalopathy can be further divided into type A, type B, and type C that results from acute liver failure, portosystemic encephalopathy (PSS), and liver cirrhosis, respectively.

Market Dynamics

Key players are indulged in conducting clinical trials for the development of new therapeutic products for the treatment for liver diseases, which is expected to drive the global hepatic encephalopathy market growth over the forecast period. For instance, in December 2019, Kaleido Biosciences, Inc., a clinical-stage healthcare company announced positive results from a proof-of-concept clinical study, in which they used KB174, a novel microbiome metabolic therapy (MMT) in combination with a 15N-labeled tracer, a biomarker of microbiome ammonia production, in patients with liver cirrhosis. The treatment reduced the 15N urinary output and was well tolerated among the patients.

Market players are engaged in launching new products, in order to expand their market share, which is expected to spur growth of the market over the forecast period. For instance, in April 2015, Lupin Pharma Canada Limited, a subsidiary of Lupin Limited, launched Zaxine, indicated for the treatment of hepatic encephalopathy, under a strategic licensing agreement with the Salix Pharmaceuticals Inc. The agreement granted Lupin Pharma Canada Limited exclusive rights for the promotion, distribution, and marketing of Zaxine in Canada.

Key features of the study:

·         This report provides an in-depth analysis of global hepatic encephalopathy market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020 – 2027), considering 2019 as the base year

·         It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

·         This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players

·         It profiles leading players in the global hepatic encephalopathy market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans

·         Key companies covered as a part of this study include ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, Norgine B.V., Abbott Laboratories, and QR Science and Technology Development Co. Ltd.

·         Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

·         The global hepatic encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

·         Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hepatic encephalopathy market.

Detailed Segmentation:

·         Global Hepatic Encephalopathy Market, By Drug Class:

o    Antibiotics

o    Laxatives

o    L-ornithine L-aspartate

o    Others

·         Global Hepatic Encephalopathy Market, By Route of Administration:

o    Oral

o    Intravenous

o    Rectal

·         Global Hepatic Encephalopathy Market, By Distribution Channel:

o    Hospital Pharmacies

o    Retail Pharmacies

o    Online Pharmacies

·         Global Hepatic Encephalopathy Market, By Region:

o    North America

§  By Country

§  U.S.

§  Canada

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

o    Latin America

§  By Country:

§  Brazil

§  Mexico

§  Argentina

§  Rest of Latin America

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

o    Europe

§  By Country:

§  U.K.

§  Germany

§  Italy

§  Spain

§  France

§  Russia

§  Rest of Europe

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

o    Asia Pacific

§  By Country:

§  Australia

§  India

§  China

§  Japan

§  ASEAN

§  South Korea

§  Rest of Asia Pacific

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

o    Middle East

§  By Country:

§  GCC

§  Israel

§  Rest of Middle East

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

o    Africa

§  By Country/Region:

§  South Africa

§  Central Africa

§  North Africa

§  By Drug Class:

§  Antibiotics

§  Laxatives

§  L-ornithine L-aspartate

§  Others

§  By Route of Administration

§  Oral

§  Intravenous

§  Rectal

§  By Distribution Channel

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

·         Company Profiles

o    ASKA Pharmaceutical Co.*

§  Company Overview

§  Product Portfolio

§  Financial Performance

§  Recent Highlights

§  Strategies

o    Cosmo Pharmaceuticals N.V.

o    Lupin Limited

o    Kaleido Biosciences

o    Kannalife Sciences, Inc.

o    Bausch Health Companies Inc.

o    Ferring Pharmaceuticals Inc.

o    Mallinckrodt Pharmaceuticals

o    Umecrine Cognition AB

o    Norgine B.V.

o    Abbott Laboratories

o    QR Science and Technology Development Co. Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Request sample copy here :

https://www.coherentmarketinsights.com/insight/request-sample/2596

Request PDF brochure here:

https://www.coherentmarketinsights.com/insight/request-pdf/2596

Click here to buy:https://www.coherentmarketinsights.com/insight/buy-now/2596

CMI Services:https://www.coherentmarketinsights.com/services

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

·        Customized Market Research Services

·        Industry Analysis Services

·        Business Consulting Services

·        Market Intelligence Services

·        Long term Engagement Model

·        Country Specific Analysis

Contact Us:   

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email :sales@coherentmarketinsights.com

Reference/Source: https://www.coherentmarketinsights.com/market-insight/hepatic-encephalopathy-market-2596